HRP20100614T1 - Soli 3,7-diamino-10h-fenotiazina i njihova uporaba - Google Patents
Soli 3,7-diamino-10h-fenotiazina i njihova uporabaInfo
- Publication number
- HRP20100614T1 HRP20100614T1 HR20100614T HRP20100614T HRP20100614T1 HR P20100614 T1 HRP20100614 T1 HR P20100614T1 HR 20100614 T HR20100614 T HR 20100614T HR P20100614 T HRP20100614 T HR P20100614T HR P20100614 T1 HRP20100614 T1 HR P20100614T1
- Authority
- HR
- Croatia
- Prior art keywords
- 4alkyl
- halogenated
- diamino
- independently selected
- 4alkenyl
- Prior art date
Links
- LZILOGCFZJDPTG-UHFFFAOYSA-N 10h-phenothiazine-3,7-diamine Chemical class C1=C(N)C=C2SC3=CC(N)=CC=C3NC2=C1 LZILOGCFZJDPTG-UHFFFAOYSA-N 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- -1 C2-4alkenyl Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
- C07D279/20—[b, e]-condensed with two six-membered rings with hydrogen atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
- C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B21/00—Thiazine dyes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- AIDS & HIV (AREA)
- Endocrinology (AREA)
Abstract
Spoj, naznačen time, da je odabran od spojeva sljedeće formule i njihovih farmaceutski prihvatljivih soli, solvata i hidrata: gdje jesvaki od R1 i R9 neovisno odabran od -H, C1-4alkila, C2-4alkenila, i halogeniranog C1-4alkila; svaki od R3NA i R3NB neovisno odabran od -H, C1-4alkila, C2-4alkenila, i halogeniranog C1-4alkila; svaki od R7NA i R7NB neovisno odabran od -H, C1-4alkila, C2-4alkenila, i halogeniranog C1-4alkila; svaki od HX1 i HX2 neovisno protična kiselina. Patent sadrži još 37 patentnih zahtjeva.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78669006P | 2006-03-29 | 2006-03-29 | |
| PCT/GB2007/001103 WO2007110627A2 (en) | 2006-03-29 | 2007-03-28 | 3,7-diamino-10h-phenothiazine salts and their use |
| EP07732164.4A EP2013191B3 (en) | 2006-03-29 | 2007-03-28 | 3,7-diamino-10h-phenothiazine salts and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20100614T1 true HRP20100614T1 (hr) | 2010-12-31 |
| HRP20100614T4 HRP20100614T4 (hr) | 2019-08-09 |
Family
ID=38421429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20100614TT HRP20100614T4 (hr) | 2006-03-29 | 2010-11-12 | Soli 3,7-diamino-10h-fenotiazina i njihova uporaba |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US7888350B2 (hr) |
| EP (1) | EP2013191B3 (hr) |
| JP (3) | JP5520043B2 (hr) |
| KR (1) | KR100983301B1 (hr) |
| CN (5) | CN104529939B (hr) |
| AT (1) | ATE478058T3 (hr) |
| AU (1) | AU2007231124B2 (hr) |
| CA (1) | CA2646163C (hr) |
| DE (1) | DE602007008550D1 (hr) |
| DK (1) | DK2013191T6 (hr) |
| EA (1) | EA014552B1 (hr) |
| ES (1) | ES2349322T7 (hr) |
| HK (4) | HK1126480A1 (hr) |
| HR (1) | HRP20100614T4 (hr) |
| IL (2) | IL194516A (hr) |
| MY (1) | MY143757A (hr) |
| PL (1) | PL2013191T6 (hr) |
| PT (1) | PT2013191E (hr) |
| WO (1) | WO2007110627A2 (hr) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7790881B2 (en) | 2004-09-23 | 2010-09-07 | Wista Laboratories Ltd. | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC) |
| ES2349322T7 (es) | 2006-03-29 | 2019-10-17 | Wista Lab Ltd | Sales de 3,7-diamino-10H-fenotiazina y su utilización |
| US8263589B2 (en) | 2006-03-29 | 2012-09-11 | Wista Laboratories Ltd. | Inhibitors of protein aggregation |
| CN101511803B (zh) | 2006-07-11 | 2012-10-31 | 维斯塔实验室有限公司 | 二氨基吩噻嗪*化合物的合成和/或纯化方法 |
| AU2008237276A1 (en) * | 2007-04-03 | 2008-10-16 | Prosetta Bioconformatics, Inc. | Phenothiazin derivatives for antiviral treatments |
| PL2167095T3 (pl) | 2007-06-19 | 2019-11-29 | Wista Lab Ltd | Związki fenotiazynowe do leczenia łagodnych zaburzeń poznawczych |
| FR2920775B1 (fr) | 2007-09-07 | 2009-11-06 | Pharma Hydro Dev P H D Soc Par | Nouveaux composes diaminophenothiazine, leur procede de preparation et leurs utilisations. |
| EP2205245B1 (en) * | 2007-10-03 | 2015-06-24 | WisTa Laboratories Ltd. | Therapeutic use of diaminophenothiazines |
| CA2745203C (en) | 2008-12-10 | 2019-06-04 | Wista Laboratories Ltd. | 3,6-disubstituted xanthylium salts |
| MY161463A (en) | 2009-09-24 | 2017-04-14 | Wista Lab Ltd | Process for the preparation of substantially pure methylthionium chloride pentahydrate form a |
| DK3792254T3 (da) * | 2009-09-24 | 2023-09-25 | Wista Lab Ltd | Krystallinske methylthioninium-chloridhydrater |
| EP2585073B1 (en) | 2010-04-30 | 2016-04-27 | Prosetta Antiviral Inc. | Antiviral compounds |
| US9192611B2 (en) | 2010-11-30 | 2015-11-24 | Wista Laboratories Ltd. | Formulations comprising methylthioninium chloride |
| US8703137B2 (en) | 2011-01-31 | 2014-04-22 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| JP5898701B2 (ja) | 2011-02-11 | 2016-04-13 | ウィスタ ラボラトリーズ リミテッド | フェノチアジンジアミニウム塩およびそれらの使用 |
| WO2012145567A1 (en) | 2011-04-20 | 2012-10-26 | Prosetta Antiviral Inc. | Antiviral compounds |
| US20130315825A1 (en) * | 2012-05-03 | 2013-11-28 | Washington University | Tricyclic heteroaromatic compounds as alpha-synuclein ligands |
| GB201512678D0 (en) | 2015-07-20 | 2015-08-26 | Wista Lab Ltd | Methods of chemical synthesis |
| CN105541756B (zh) * | 2015-12-17 | 2018-02-09 | 陕西方舟制药有限公司 | 一种制备1‑(3，7‑双二甲氨基‑吩噻嗪‑10‑基)乙酮的方法 |
| ITUA20163526A1 (it) * | 2016-05-17 | 2017-11-17 | Icrom Spa | Procedimento per la preparazione di composti diamminofenotiazinici ad elevato grado di purezza |
| KR102475825B1 (ko) | 2016-07-25 | 2022-12-08 | 위스타 레보레이토리스 리미티드 | 디아미노페노티아진 (diaminophenothiazines)의 투여 및 투여량 (dosage) |
| GB201614834D0 (en) * | 2016-09-01 | 2016-10-19 | Wista Lab Ltd | Treatment of dementia |
| GB201621817D0 (en) * | 2016-12-21 | 2017-02-01 | Wista Lab Ltd | Methods of chemical synthesis |
| CN107253936B (zh) * | 2017-06-23 | 2021-07-23 | 复旦大学 | 一类可用于次氯酸检测的荧光探针及其制备方法和应用 |
| CN108129418A (zh) * | 2017-12-22 | 2018-06-08 | 郑州大学 | 吩噻嗪-氨基二硫代甲酸酯衍生物及其制备方法和应用 |
| KR20210038586A (ko) | 2018-07-26 | 2021-04-07 | 위스타 레보레이토리스 리미티드 | 집단에서 디아미노페노티아진(diaminophenothiazines)의 최적 투여량 |
| KR20240132122A (ko) | 2018-09-05 | 2024-09-02 | 젠팅 타우알엑스 다이어그노스틱 센터 에스디엔 비에이치디 | 신경퇴행성 질환에 대한 네트워크 방법 |
| CN109223800A (zh) * | 2018-10-26 | 2019-01-18 | 辽宁大学 | 3,7-二对甲苯胺基-吩噻嗪-5-鎓碘化物与超声协同在抑制肿瘤细胞增殖中的应用 |
| CA3135170A1 (en) | 2019-04-05 | 2020-10-08 | Tauc3 Biologics Limited | Anti-tauc3 antibodies and uses thereof |
| GB201909454D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
| GB201909493D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
| GB201909506D0 (en) | 2019-07-02 | 2019-08-14 | Wista Lab Ltd | Synaptopathies |
| BR112022022322A2 (pt) | 2020-05-05 | 2022-12-13 | Wista Lab Ltd | Compostos de metiltionínio para uso no tratamento de hipoxemia |
| GB202006659D0 (en) | 2020-05-05 | 2020-06-17 | Wista Lab Ltd | Therapeutic treatments |
| CA3181393A1 (en) | 2020-05-05 | 2021-11-11 | Wista Laboratories Ltd. | Methylthioninium compounds for use in the treatment of covid-19 |
| GB202010652D0 (en) | 2020-07-10 | 2020-08-26 | Wista Lab Ltd | Anti-tau antibodies |
| DE102020212508A1 (de) | 2020-10-02 | 2022-04-07 | Continental Reifen Deutschland Gmbh | Verbindung, Kautschukmischung enthaltend die Verbindung, Fahrzeugreifen, der die Kautschukmischung in wenigstens einem Bauteil aufweist, Verfahren zur Herstellung der Verbindung sowie Verwendung der Verbindung als Alterungsschutzmittel und/oder Antioxidationsmittel und/oder Antiozonant und/oder Farbstoff |
| GB202204185D0 (en) | 2022-03-24 | 2022-05-11 | Wista Lab Ltd | Oral treatment |
| WO2023232764A1 (en) | 2022-05-31 | 2023-12-07 | Wista Laboratories Ltd. | Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds |
| WO2024061971A1 (en) | 2022-09-21 | 2024-03-28 | Wista Laboratories Ltd. | Novel formulations and vehicles |
| WO2024184146A1 (en) | 2023-03-03 | 2024-09-12 | Wista Laboratories Ltd. | Diaminophenothiazine for the treatment of microvascular brain disease disease |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE569430A (hr) | 1957-07-17 | |||
| US3641016A (en) * | 1968-02-16 | 1972-02-08 | Egyt Gyogyszervegyeszeti Gyar | Thionine derivatives |
| JPS52105931A (en) * | 1976-03-02 | 1977-09-06 | Mita Industrial Co Ltd | New leuco coloring matters and process for manufacture thereof |
| US4309255A (en) | 1980-09-10 | 1982-01-05 | International Business Machines Corporation | Electrochromic recording paper |
| US4622395A (en) | 1984-10-01 | 1986-11-11 | Minnesota Mining And Manufacturing Company | Phenoxazine and phenothiazine dyes and leuco forms thereof |
| US4647525A (en) | 1984-10-01 | 1987-03-03 | Minnesota Mining And Manufacturing Company | Stabilized leuco phenazine dyes and their use in an imaging system |
| GB8724412D0 (en) | 1987-10-19 | 1987-11-25 | Medical Res Council | Protein |
| US5571666A (en) | 1988-10-28 | 1996-11-05 | Oklahoma Medical Research Foundation | Thiazine dyes used to inactivate HIV in biological fluids |
| CA2011116C (en) * | 1989-03-06 | 1999-11-16 | Murray A. Kaplan | Lyophilized bmy-28142 dihydrochloride for parenteral use |
| US5220009A (en) * | 1990-05-03 | 1993-06-15 | Yeda Research And Development Company Limited | Phenothiazinium salts and their use for disinfecting aqueous effluents |
| JPH0725786A (ja) | 1990-05-16 | 1995-01-27 | Univ Rockefeller | アルツハイマー病を伴うアミロイドーシスの治療 |
| EP0600951A4 (en) | 1991-08-01 | 1996-10-30 | Paul H Voorheis | Diagnostic method for alzheimer's disease. |
| WO1993003177A1 (en) | 1991-08-09 | 1993-02-18 | Massachusetts Institute Of Technology | Novel tau/neurofilament protein kinases |
| DE4140192C2 (de) | 1991-12-05 | 1996-02-29 | Alfatec Pharma Gmbh | Sol-gesteuerte Thermokolloidmatrix auf Gelatinebasis für perorale Retardformen |
| EP0618968B1 (en) | 1991-12-06 | 1999-10-13 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Tools for the diagnosis and treatment of alzheimer's disease |
| JPH06289015A (ja) | 1993-03-30 | 1994-10-18 | Sunstar Inc | フェノチアジン系色源体安定化組成物 |
| GB9316727D0 (en) | 1993-08-12 | 1993-09-29 | Inst Of Psychiatry | Models of alzheimers's disease |
| GB9317193D0 (en) | 1993-08-18 | 1993-10-06 | Zeneca Ltd | Method |
| EP0778773A1 (en) | 1994-08-08 | 1997-06-18 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes |
| DE4430091A1 (de) | 1994-08-25 | 1996-02-29 | Bayer Ag | Verwendung von N-substituierten Phenothiazinen |
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| US5804601A (en) | 1995-04-10 | 1998-09-08 | Takeda Chemical Industries, Ltd. | Aromatic hydroxamic acid compounds, their production and use |
| US5693638A (en) | 1996-02-23 | 1997-12-02 | Myers; Daniel | Method of treating a migraine headache |
| US6333322B1 (en) | 1996-03-13 | 2001-12-25 | Eisai Co., Ltd. | Nitrogen-containing tricyclic compounds and drugs containing the same |
| EP0973383A4 (en) | 1997-01-21 | 2001-08-22 | American Nat Red Cross | INTRACELLULAR AND EXTRACELLULAR DECONTAMINATION OF WHOLE BLOOD AND BLOOD COMPONENTS WITH AMPHIPHILEN PHENOTHIAZINE-5-IUM DYES AND LIGHT |
| WO1999062548A1 (en) | 1998-06-01 | 1999-12-09 | Advanced Research And Technology Institute | Methods and compositions for diagnosing tauopathies |
| FR2788436A1 (fr) | 1999-01-14 | 2000-07-21 | Pf Medicament | Composition d'un derive de phenothiazine |
| WO2001053340A2 (en) | 2000-01-21 | 2001-07-26 | Pharmacia & Upjohn Company | Transgenic mouse model of human neurodegenerative disease |
| GB0017060D0 (en) | 2000-07-11 | 2000-08-30 | Hunter Fleming Ltd | Production, stabilisation and use of reduced forms of pharmaceutical compounds |
| GB0100119D0 (en) | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0101049D0 (en) * | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| US20020197258A1 (en) | 2001-06-22 | 2002-12-26 | Ghanbari Hossein A. | Compositions and methods for preventing protein aggregation in neurodegenerative diseases |
| GB0117326D0 (en) | 2001-07-16 | 2001-09-05 | Univ Aberdeen | Napthoquinone-type inhibitors of protein aggregation |
| US7410965B2 (en) | 2002-05-29 | 2008-08-12 | Gruenenthal Gmbh | Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol |
| US6953974B2 (en) * | 2003-08-26 | 2005-10-11 | Texas Instruments Incorporated | EEPROM device and method for providing lower programming voltage |
| GB0322756D0 (en) | 2003-09-29 | 2003-10-29 | Univ Aberdeen | Methods of chemical synthesis |
| AU2004295148A1 (en) | 2003-11-28 | 2005-06-16 | Photopharmica Limited | Developments in biologically active methylene blue derivatives (2) |
| US7790881B2 (en) | 2004-09-23 | 2010-09-07 | Wista Laboratories Ltd. | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC) |
| SI2322517T1 (sl) | 2004-09-23 | 2019-06-28 | Wista Laboratories Ltd. | Postopki za kemijsko sintezo in čiščenje diaminofenotiazinijevih spojin, vključno metiltioninijevega klorida (MTC) |
| US20070116757A1 (en) | 2005-11-08 | 2007-05-24 | Collegium Pharmaceutical, Inc. | Methylene Blue Derivatives |
| ES2349322T7 (es) | 2006-03-29 | 2019-10-17 | Wista Lab Ltd | Sales de 3,7-diamino-10H-fenotiazina y su utilización |
| US8263589B2 (en) | 2006-03-29 | 2012-09-11 | Wista Laboratories Ltd. | Inhibitors of protein aggregation |
| CN101511803B (zh) | 2006-07-11 | 2012-10-31 | 维斯塔实验室有限公司 | 二氨基吩噻嗪*化合物的合成和/或纯化方法 |
| PL2167095T3 (pl) | 2007-06-19 | 2019-11-29 | Wista Lab Ltd | Związki fenotiazynowe do leczenia łagodnych zaburzeń poznawczych |
| EP2205245B1 (en) | 2007-10-03 | 2015-06-24 | WisTa Laboratories Ltd. | Therapeutic use of diaminophenothiazines |
| JP5898701B2 (ja) | 2011-02-11 | 2016-04-13 | ウィスタ ラボラトリーズ リミテッド | フェノチアジンジアミニウム塩およびそれらの使用 |
-
2007
- 2007-03-28 ES ES07732164T patent/ES2349322T7/es active Active
- 2007-03-28 US US12/294,599 patent/US7888350B2/en active Active
- 2007-03-28 DK DK07732164.4T patent/DK2013191T6/en active
- 2007-03-28 EP EP07732164.4A patent/EP2013191B3/en active Active
- 2007-03-28 CA CA2646163A patent/CA2646163C/en active Active
- 2007-03-28 KR KR1020087026537A patent/KR100983301B1/ko active IP Right Review Request
- 2007-03-28 PT PT07732164T patent/PT2013191E/pt unknown
- 2007-03-28 CN CN201510002371.8A patent/CN104529939B/zh active Active
- 2007-03-28 CN CN201510002365.2A patent/CN104606199B/zh active Active
- 2007-03-28 AU AU2007231124A patent/AU2007231124B2/en active Active
- 2007-03-28 DE DE602007008550T patent/DE602007008550D1/de active Active
- 2007-03-28 CN CN201410269784.8A patent/CN104119294B/zh active Active
- 2007-03-28 CN CN200780020349.XA patent/CN101460472B/zh active Active
- 2007-03-28 CN CN201811196758.1A patent/CN109384741B/zh active Active
- 2007-03-28 PL PL07732164T patent/PL2013191T6/pl unknown
- 2007-03-28 JP JP2009502205A patent/JP5520043B2/ja active Active
- 2007-03-28 MY MYPI20083821A patent/MY143757A/en unknown
- 2007-03-28 EA EA200870384A patent/EA014552B1/ru unknown
- 2007-03-28 AT AT07732164T patent/ATE478058T3/de unknown
- 2007-03-28 WO PCT/GB2007/001103 patent/WO2007110627A2/en active Application Filing
-
2008
- 2008-10-02 IL IL194516A patent/IL194516A/en active IP Right Grant
-
2009
- 2009-06-05 HK HK09105064.1A patent/HK1126480A1/xx active IP Right Maintenance
-
2010
- 2010-11-12 HR HRP20100614TT patent/HRP20100614T4/hr unknown
-
2013
- 2013-02-14 JP JP2013026635A patent/JP5814957B2/ja active Active
- 2013-11-14 JP JP2013236080A patent/JP2014055165A/ja active Pending
-
2014
- 2014-04-03 IL IL231890A patent/IL231890A/en active IP Right Grant
- 2014-12-24 HK HK14112923.1A patent/HK1199444A1/xx unknown
-
2015
- 2015-10-13 HK HK15109987.9A patent/HK1209417A1/xx unknown
- 2015-10-30 US US14/929,111 patent/US11344558B2/en active Active
- 2015-11-06 HK HK15110959.1A patent/HK1210047A1/xx unknown
-
2022
- 2022-02-02 US US17/591,306 patent/US11951110B2/en active Active
-
2024
- 2024-03-05 US US18/595,985 patent/US20240245700A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100614T1 (hr) | Soli 3,7-diamino-10h-fenotiazina i njihova uporaba | |
| HRP20080666T3 (hr) | Antagonisti cgrp receptora | |
| RS51200B (sr) | (imidazol-1-il-metil)-piridazin kao blokator nmda receptora | |
| SE0400284D0 (sv) | Novel compounds | |
| TW200728307A (en) | Novel spirochromanone derivatives | |
| WO2008005368A3 (en) | Piperazines as p2x7 antagonists | |
| WO2005110410A3 (en) | Kinase inhibitors as therapeutic agents | |
| RS51007B (sr) | Supstituisani piridinil i pirimidinil derivati kao modulatori metabolizma i lečenje poremećaja proisteklih iz toga | |
| HRP20120323T1 (hr) | Spoj diaril-hidantoina | |
| MY151003A (en) | Stable pharmaceutical composition comprising a pyrimidine-sulfamide | |
| EA200602060A1 (ru) | Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы | |
| RS53293B (en) | CYTOTOXIC AGENTS CONTAINING NEW TOMAIMYCIN DERIVATIVES AND THEIR THERAPY | |
| KR20050085991A (en) | Compounds exhibiting thrombopoietin receptor agonism | |
| HRP20090162T1 (hr) | Kinolinon-karboksamidni spojevi kao agonisti 5-ht4 receptora | |
| DE602004008098D1 (de) | Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren | |
| ATE297910T1 (de) | Retinoid x rezeptormodulatoren | |
| HRP20080027T3 (hr) | 4-hidroksi-4-metil-piperidin-1-karboksilna kiselina (4-metoksi-7-morfolin-4-il-benzotiazol-2-il)-amid | |
| HRP20040686B1 (hr) | Novi heterocikliäśki spojevi koji djeluju kao inhibitori beta-laktamaza | |
| MX2011012628A (es) | Derivados amino-propionicos sustituidos como inhibidores de neprilisina. | |
| CY1113657T1 (el) | Νεα παραγωγα βενζοφαινονης ή αλατα αυτων | |
| TW200745029A (en) | Sulfonamide derivatives exhibiting PGD2 receptor antagonism | |
| DE602006011752D1 (de) | Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate | |
| RS52953B (en) | PYRIDOPINIDINONSKI INHIBITORI PI3 KALFA | |
| MXPA05011411A (es) | 1,4-diazepinas sustituidas y usos de las mismas. | |
| RS53142B (en) | UNITS THAT HAVE ANTAGONISTIC ACTIVITY ON CRTH2 |